William P. Harris, MD

William Harris, MD, presents the study design and rationale for HCRN GI15-225, an open-label, single-arm multicenter, pilot study exploring whether using immunotherapy drugs in combination with locoregional therapies for patients with non-metastatic HCC is safe and beneficial, using pembrolizumab every 3 weeks starting 1 week before initial Y90 radioembolization.

William P. Harris, MD, discusses remaining questions regarding treatment sequencing after atezolizumab and bevacizumab in hepatocellular carcinoma.

William P. Harris, MD, discusses updated data from the phase 3 IMbrave150 study in hepatocellular carcinoma.

William P. Harris, MD, discusses the adoption of immunotherapy in advanced hepatocellular carcinoma.